Merck & Company, Inc. (NYSE:MRK) PT Set at $70.00 by J P Morgan Chase & Co

J P Morgan Chase & Co set a $70.00 price objective on Merck & Company, Inc. (NYSE:MRK) in a research note issued to investors on Sunday, October 29th. The firm currently has a buy rating on the stock.

A number of other analysts also recently issued reports on MRK. BMO Capital Markets reaffirmed a sell rating on shares of Merck & in a report on Wednesday, July 5th. Citigroup Inc. set a $65.00 target price on Merck & and gave the company a hold rating in a report on Wednesday, July 5th. BidaskClub downgraded Merck & from a hold rating to a sell rating in a report on Tuesday, July 11th. Deutsche Bank AG reissued a hold rating and issued a $66.00 target price (up from $64.00) on shares of Merck & in a report on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a neutral rating and set a $74.00 price objective (up from $70.00) on shares of Merck & in a research note on Thursday, July 27th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of Hold and an average target price of $67.07.

Merck & (NYSE MRK) opened at $54.99 on Friday. Merck & has a 1 year low of $54.41 and a 1 year high of $66.80. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43. The company has a market capitalization of $150,116.47, a P/E ratio of 14.16, a P/E/G ratio of 2.37 and a beta of 0.78.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The business had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. During the same period in the previous year, the firm posted $1.07 earnings per share. The company’s revenue was down 2.0% on a year-over-year basis. analysts forecast that Merck & will post 3.95 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://weekherald.com/2017/11/15/merck-company-inc-mrk-given-a-70-00-price-target-at-j-p-morgan-chase-co.html.

In related news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.25% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Merck & by 1.7% during the second quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock valued at $12,442,709,000 after acquiring an additional 3,312,459 shares in the last quarter. BlackRock Inc. grew its stake in Merck & by 1.0% in the second quarter. BlackRock Inc. now owns 184,997,390 shares of the company’s stock worth $11,856,484,000 after purchasing an additional 1,834,500 shares in the last quarter. Franklin Resources Inc. grew its stake in Merck & by 3.1% in the second quarter. Franklin Resources Inc. now owns 27,019,572 shares of the company’s stock worth $1,731,684,000 after purchasing an additional 801,033 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in Merck & by 7.5% in the third quarter. Ameriprise Financial Inc. now owns 23,515,877 shares of the company’s stock worth $1,505,621,000 after acquiring an additional 1,631,013 shares during the last quarter. Finally, Boston Partners lifted its holdings in Merck & by 2.6% in the first quarter. Boston Partners now owns 19,935,016 shares of the company’s stock worth $1,266,671,000 after acquiring an additional 500,476 shares during the last quarter. Institutional investors own 73.15% of the company’s stock.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply